Back to Results
First PageMeta Content
AstraZeneca / Health / Influenza vaccines / Orthomyxoviridae / Flu pandemic / FluMist / MedImmune / Influenza / Immunogenicity / Vaccination / Vaccines / Medicine


According to the CBER Manual of Standard Operating Procedures and Policies, Regulatory - License Applications, SOPP 8404: Refu
Add to Reading List

Open Document

File Size: 129,34 KB

Share Result on Facebook

Company

MedImmune LLC / MANUFACTURING AND CONTROL Manufacturing / /

Country

United States / /

Event

FDA Phase / /

Facility

No facility / /

IndustryTerm

final product / prevention of influenza disease / manufacturing / manufacturing process / /

MedicalCondition

allergic reaction / influenza disease / disease / strain / Sterility / influenza A / cold-adapted live attenuated influenza / purified influenza viruses / influenza viruses / hypersensitivity / infection / both influenza / Influenza / /

MedicalTreatment

Active immunization / vaccination / /

Organization

Approval Offices Signatory Authority / Review Committee / office of Vaccines Research / /

Person

Anil Choudhary / Meghan Ferris / Christian Sauder / Victoria Lineage / Chiang Syin / Steven Kunder / Wellington Sun / Karen Campbell / Lisa Stockbridge / Hector Izurieta / Lillian Ortega / Maryann Gallagher / Lot Release / Jane Woo / Zhiping Ye / Sang Ahnn / /

Position

Chair / General / Director / Division of Vaccines and Related Product / /

Product

Gentamicin sulfate / BLA / BLA supplement / quadrivalent / FluMist / FluMist® Quadrivalent / FluMist® / /

ProvinceOrState

Maryland / /

Technology

antibodies / /

SocialTag